Prosecution Insights
Last updated: November 04, 2026
Application No. 18/060,894

COMPOSITIONS COMPRISING COOLNESS-REGULATING AGENT, AND METHOD OF USE THEREOF

Final Rejection §102§103
Filed
Dec 01, 2022
Priority
Dec 03, 2021 — provisional 63/264,895 +1 more
Examiner
WEBB, WALTER E
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Epc Natural Products Co. Ltd.
OA Round
2 (Final)
46%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
65%
With Interview

Examiner Intelligence

Grants 46% of resolved cases
46%
Career Allowance Rate
465 granted / 1005 resolved
-13.7% vs TC avg
Strong +19% interview lift
Without
With
+18.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
56 currently pending
Career history
1065
Total Applications
across all art units

Statute-Specific Performance

§101
0.8%
-39.2% vs TC avg
§103
52.1%
+12.1% vs TC avg
§102
14.7%
-25.3% vs TC avg
§112
16.3%
-23.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1005 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicants' arguments, filed 04/29/2026, have been fully considered. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. Claim Rejections - 35 USC § 102/103—New by Amendment The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1, 3-6, 8-9, 21 is/are rejected under 35 U.S.C. 102(a)(1) as anticipated by or, in the alternative, under 35 U.S.C. 103 as obvious over Shi et al., (WO2019/217269). Shi et al. teaches “products, uses thereof, compositions thereof, and methods to prepare products formed from Maillard reaction products from a sugar donor and/or sweet tea extracts, stevia extracts, swingle (mogroside) extracts, one or more sweet tea extract components, one or more steviol glycosides, one or more mogrosides, one or more glycosylated sweet tea glycosides, one or more glycosylated steviol glycosides or one or more glycosylated mogrosides and an amine donor/reactant” (Abstract). Shi et al. further teaches, “Maillard reactions create unique orthonasal and retronasal taste(s). The typically associated off-taste of stevia glycosides is either removed or masked with MRPs added to the stevia glycoside(s) and creates an overall good smell and taste of the resulting composition. MRPs increase the bitterness threshold to stevia glycosides and enhance intensity of sweetness, thus making stevia glycosides useful for sugar replacement or sugar reduction in a product. The inventors have surprisingly found the flavor of compositions herein, are the result of the process not only characterized by Maillard reaction between sugar donor and amine donor, but also is synergized by different groups of stevia glycosides with or without non-stevia glycosides substances. . . The initial SGs’ typical undesired taste features are thus concealed by the process . . .” (p. 5, para. [0020]). The prior art teaches a generic embodiment of “A sweetener or flavoring composition comprising: (1) a first component comprising a Maillard reaction product (MRP) composition formed from a reaction mixture comprising: (a) one or more Stevia-related components selected from the group consisting of Stevia extracts, glycosylated Stevia extracts, steviol glycosides, and glycosylated steviol glycosides, and . . .wherein the first and second components are present in the sweetener composition in a concentration range of 1-100 wt% of the sweetener composition” (p. 435-436, paras. [003877]-[003882). The prior art teaches specific embodiment of a “dairy product” (consumable; clm. 8), “wherein the first and second components are present in the dairy product in a concentration of 0.01-1% wt % of the dairy product” (p. 440, para. [003934]). Accordingly, the prior art anticipates the claimed range of 0.001-25 wt% for the agent. The compositions are also taught to comprise “unreacted reducing sugar(s) and/or a portion of unreacted amine donor(s)”, including “unreacted GSG” (p. 428, para. [003792]), as per claim 4. The prior art composition further comprises flavoring agents such as “menthol” (p. 91, para. [00515]), as per claims 5-6, “bitter almonds” (p. 42, para. [00374]), which suffices as a bitter substance, as per claim 9. The prior art is anticipatory insofar as it teaches a composition comprising an MRP-glycosylated stevia glycoside steviol glycoside (GSG-MRPs) within the claimed range of 0.001-25 wt% (clm 2), which is suitable to regulate a cooling effect or taste. Assuming, purely arguendo, that the prior art teaching is not specific enough to give rise to anticipation it would have been obvious to a person having ordinary skill in the art at the time of applicant’s filing to provide a composition comprising MRP of stevia related components, e.g., GSG-MRPs, within the claimed range in view of the teaching of Shi et al. above. Claim Rejections - 35 USC § 103—New by Amendment The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1, 3-6, 8-9, 21 is/are rejected under 35 U.S.C. 103 as being unpatentable over Lee (KR1020140082504) in view of Shi et al., (WO2019/217269). Lee teaches a toothpaste composition comprising “silicon dioxide 1.0 weight%, sodium monofluorophosphate 0.37 weight%, D- sorbitol liquid 63 weight%, glycerine 0.8~1.2 weight%, polyethylene glycol (PEG-1500) 1.5~2.5 weight%, carboxymethylcellulose sodium 0.8~1.5 weight%, hydrated silicic acid 3.5~4.5 weight%, xylitol 0.2~1.2 weight%, steviol glycoside 0.1~1 weight%, green tea extract 0.1~1.5 weight%, sage extract 0.1~1.5 weight%, ginseng extract 0.5~1.5 weight%, propolis extract 0.1~1.5 weight%, oyster 0.1~1 weight%, (L) - menthol 0.1~2 weight%, call mint odor (HF-61399) 0.2~1.5 weight%, combination perfume (apple essence) (HF-30630) 0.1~1.5 weight% and purified water 25~35 weight%” (Abstract). The one or more steviol glycosides “can make up 1%” of the compositions (p. 74, para. [00488]). The prior art composition further comprises menthol, as per claim 5, mint odor or xylitol, which suffices as a flavoring substance, as per claim 6, sage extract, which suffices as a bitter substance, as per claim 9. The prior art toothpaste is a consumable product, as per claims 8-9 insofar as it is an oral hygiene product (see Specification at p. 29, [0126-0127]). Lee does not teach a Maillard Reaction Product of stevia glycoside. Shi et al. teaches products, uses thereof, compositions thereof, and methods to prepare products formed from Maillard reaction products from a sugar donor and/or sweet tea extracts, stevia extracts, swingle (mogroside) extracts, one or more sweet tea extract components, one or more steviol glycosides, one or more mogrosides, one or more glycosylated sweet tea glycosides, one or more glycosylated steviol glycosides or one or more glycosylated mogrosides and an amine donor/reactant” (Abstract). Shi et al. further teaches the advantage of providing a Maillared reaction product, i.e., “Maillard reactions create unique orthonasal and retronasal taste(s). The typically associated off-taste of stevia glycosides is either removed or masked with MRPs added to the stevia glycoside(s) and creates an overall good smell and taste of the resulting composition. MRPs increase the bitterness threshold to stevia glycosides and enhance intensity of sweetness, thus making stevia glycosides useful for sugar replacement or sugar reduction in a product. The inventors have surprisingly found the flavor of compositions herein, are the result of the process not only characterized by Maillard reaction between sugar donor and amine donor, but also is synergized by different groups of stevia glycosides with or without non-stevia glycosides substances. . . The initial SGs’ typical undesired taste features are thus concealed by the process . . .” (p. 5, para. [0020]). The compositions are also taught to comprise “unreacted reducing sugar(s) and/or a portion of unreacted amine donor(s)”, including “unreacted GSG” (p. 428, para. [003792]), as per claim 4, as part of the sweetening composition. It would have been obvious to a person having ordinary skill in the art at the time of applicant’s filing to use e.g. MRP glycosylated stevia glycoside as the stevia glycoside sweetener in the compositions of Lee for the advantage of avoiding the off-taste of stevia creating an overall good smell and taste for the resulting composition, as taught by Shi et al. Response to Arguments Applicant argues for withdrawal of the prior art in view of the amended claims. However, a new ground of rejection was made in response to the amended claims. Accordingly, Applicant’s argument is moot at this time in view of the new ground of rejection above. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Any inquiry concerning this communication or earlier communications from the examiner should be directed to WALTER E WEBB whose telephone number is (571)270-3287 and fax number is (571) 270-4287. The examiner can normally be reached from Mon-Fri 7-3:30. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana Kaup can be reached (571) 272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Walter E. Webb /WALTER E WEBB/Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Dec 01, 2022
Application Filed
Jun 09, 2023
Response after Non-Final Action
Jan 30, 2026
Non-Final Rejection mailed — §102, §103
Apr 29, 2026
Response Filed
Aug 31, 2026
Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778860
Delivery Carrier For Tooth Whitening
4y 11m to grant Granted Nov 03, 2026
Patent 12778874
Catalase Composition with Improved Stability and Methods
4y 1m to grant Granted Nov 03, 2026
Patent 12773379
METHODS OF USE OF ORAL CARE COMPOSITIONS COMPRISING HOPS
2y 5m to grant Granted Oct 27, 2026
Patent 12758476
ACID RESISTANT COMPOSITION HAVING IMPROVED SOLUBILITY
4y 4m to grant Granted Oct 13, 2026
Patent 12758483
ANTIBACTERIAL AND MINERALIZING COMPOSITIONS AND METHODS OF USE THEREOF
3y 1m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
46%
Grant Probability
65%
With Interview (+18.8%)
3y 4m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1005 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month